PRIME PEOPLE | GIORGIO PISANI |
IBSA FARMACEUTICI GIORGIO PISANI The President of IBSA Farmaceutici Italia speaks to PRIME about the company's
emergence into the aesthetic medicine market and their new product PROFHILO®, which launches at the AMWC in Monaco
What is your role within the company? I am the President of IBSA Farmaceutici Italia, the Italian subsidiary of the multinational pharmaceutical group IBSA Institut Biochimique SA, based in Lugano, Switzerland. IBSA Group is present in 70 countries
and has a turnover of €500 million, with more than 10 production plants, two of which are located in China for the raw material production of fertility hormones. IBSA Italia has one office in Italy’s capital,
Rome and three offices including the headquarters and 2 production facilities in the north of Italy (close to Milan). In the southern part of the country a state-of-the- art biotechnological facility is present and able to produce, by means of biofermentation, 150 kg per year of hyaluronic acid (HA) from pharmaceutical to cosmetic grade. With the main focus on research and
74 ❚
production of specialised pharmaceutical and medical devices, IBSA Italia has become a European leader in the preparation of hyaluronic acid products intended for the orthopaedic, respiratory, dermatology, and dermoaesthetic markets. The formulations
March 2015 |
prime-journal.com
are all innovative and made in highly specialised production plants GMP (good manufacturing practice) approved. The company also offers contract
manufacturing services for the pharmaceutical and nutritional industry, at an international level. The production lines are injectable pharmaceutical forms (either aeseptic or with terminal sterilisation), topicals, suppositories and ovules, medical devices, and nutritional products in soft gelatin capsules. The ongoing commitment to innovation
and strong investments in research and development have distinguished IBSA in the market as one of the few companies in the world able to control the entire lifecycle of hyaluronic acid products, starting from the production of the raw material
to
the ready-to- use finished product in pre- filled syringes.
How important is the dermatology and aesthetic medicine market to IBSA? The consolidated experience of the IBSA group in developing and producing products based on hyaluronic acid has resulted in the development of a dermatological line that is distinguished by its high standard of quality and safety. The products in this range, available in
IBSA Group is present
in 70 countries and has a turnover of €500 million, with more than 10
production plants, two of
which are located in China for the raw material
production of fertility hormones.
various formulations, are able to intervene where necessary with the topical application of hyaluronic acid (e.g. infected and non-infected wounds, leg ulcers, bedsores, post-operative wounds, burns, dermatological disorders of bacterial origin or those predisposed to developing secondary infections), thus encouraging resumption of functionality and skin integrity. IBSA has only recently
approached the world of aesthetic medicine, but with clear and coherent ideas regarding the business philosophy. IBSA believes that the trump card in this
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96